Get started
Keyword

idelalisib

Description: Idelalisib is an anticancer drug that inhibits phosphoinositide 3-kinase delta and is used to treat certain B-cell malignancies.
Wikidata ID: wiki/Q5908266
OpenAlex ID: keywords/idelalisib
The PI3K Pathway in Human Disease
2017 · David A. Fruman, Honyin Chiu, et al. · Cell · 2,706
PDF
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
2014 · Richard R. Furman, Jeff P. Sharman, et al. · New England Journal of Medicine · 1,710
PDF
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
2014 · Ajay K. Gopal, Brad S. Kahl, et al. · New England Journal of Medicine · 1,069
PDF
Targeting the PI3K pathway in cancer: are we making headway?
2018 · Filip Janku, Timothy A. Yap, et al. · Nature Reviews Clinical Oncology · 1,017
The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
2008 · Adrian J. Folkes, Khatereh Ahmadi, et al. · Journal of Medicinal Chemistry · 741
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
2010 · Brian J. Lannutti, Sarah A. Meadows, et al. · Blood · 720
PDF
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011 · Johanna C. Bendell, Jordi Rodon, et al. · Journal of Clinical Oncology · 686
PDF
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
2014 · Jennifer R. Brown, John C. Byrd, et al. · Blood · 590
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
2011 · Julia Hoellenriegel, Sarah A. Meadows, et al. · Blood · 549
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
2010 · Sarah E. M. Herman, Amber L. Gordon, et al. · Blood · 543
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
2019 · Michael Hallek · American Journal of Hematology · 504
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
2015 · G S Choudhary, S Al-harbi, et al. · Cell Death and Disease · 391
PDF
Chronic lymphocytic leukaemia
2018 · Michael Hallek, Tait D Shanafelt, et al. · The Lancet · 373
Management of adverse events associated with idelalisib treatment: expert panel opinion
2015 · Steven E. Coutré, Jacqueline C. Barrientos, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 310
PDF
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
2017 · Steven M. Horwitz, Raphael Koch, et al. · Blood · 289
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
2016 · Benjamin L. Lampson, Siddha N. Kasar, et al. · Blood · 285
PDF
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
2017 · Michael Hallek · American Journal of Hematology · 282
PDF
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
2016 · Klaus Okkenhaug, Mariona Graupera, et al. · Cancer Discovery · 264
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
2015 · Michael Hallek · American Journal of Hematology · 263
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
2010 · Carol O'Brien, Jeffrey J. Wallin, et al. · Clinical Cancer Research · 255
PDF
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
2013 · Akintunde Akinleye, Parthu Avvaru, et al. · Journal of Hematology & Oncology · 254
PDF
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
2014 · Brad S. Kahl, Stephen E. Spurgeon, et al. · Blood · 252
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
2017 · Andrew D Zelenetz, Jacqueline C Barrientos, et al. · The Lancet Oncology · 250
PDF
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
2015 · Susan M. O'Brien, Nicole Lamanna, et al. · Blood · 241
PDF
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
2023 · Mazyar Shadman · JAMA · 239
Works count: 2,093
Citation count: 40,750
Year
Topic
Type